Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies
-
Published:2023-12-15
Issue:
Volume:
Page:jrheum.2023-0920
-
ISSN:0315-162X
-
Container-title:The Journal of Rheumatology
-
language:en
-
Short-container-title:J Rheumatol
Author:
Skydel Joshua J.ORCID,
Ramachandran ReshmaORCID,
Suttiratana SakinahORCID,
Ross Joseph S.ORCID,
Burns Christopher M.,
Wallach Joshua D.ORCID
Abstract
Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies.1Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials.2
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology